We propose that the diabetic status and NOTCH-NRG1-HER3 axis can be used as prognostic markers to predict responses to HER2-targeted therapy, offering a therapeutic strategy for treating breast cancer patients with diabetes. Here, ERBB2 is linked to breast carcinoma.